{"id":63083,"date":"2026-04-14T14:30:40","date_gmt":"2026-04-14T06:30:40","guid":{"rendered":"https:\/\/flcube.com\/?p=63083"},"modified":"2026-04-14T14:30:41","modified_gmt":"2026-04-14T06:30:41","slug":"harbin-gloria-pharmaceuticals-acquires-neurodegenerative-disease-candidate-from-capital-medical-university-for-rmb-14-15m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63083","title":{"rendered":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M"},"content":{"rendered":"\n<p><strong>Harbin Gloria Pharmaceuticals Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002437:SHE\">SHE: 002437<\/a>) announced the signing of a <strong>technology transfer agreement<\/strong> with <strong>Capital Medical University (CMU)<\/strong>, acquiring patent rights for &#8220;<strong>An isoquinoline derivative and its synthesis method and application<\/strong>&#8221; at a transaction price of <strong>RMB 14.15 million<\/strong> (approximately <strong>USD 2 million<\/strong>). The compound represents a <strong>preclinical candidate<\/strong> targeting <strong>neurodegenerative diseases associated with glucose metabolism disorders<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437)<\/td><\/tr><tr><td><strong>Technology Provider<\/strong><\/td><td>Capital Medical University (CMU)<\/td><\/tr><tr><td><strong>Asset Acquired<\/strong><\/td><td>Patent rights for isoquinoline derivative compound<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>RMB 14.15 million (USD 2 million)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical candidate compound<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Neurodegenerative diseases linked to glucose metabolism disorders<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-compound-profile-amp-mechanism-of-action\">Compound Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chemical Class:<\/strong> Novel isoquinoline derivative with proprietary synthesis method<\/li>\n\n\n\n<li><strong>Target:<\/strong> Phosphoglycerate kinase 1 (<strong>Pgk1<\/strong>) \u2013 key enzyme in glycolytic pathway<\/li>\n\n\n\n<li><strong>Blood-Brain Barrier Penetration:<\/strong> Demonstrated ability to cross the blood-brain barrier, critical for CNS-targeted therapies<\/li>\n\n\n\n<li><strong>Primary Mechanism:<\/strong> Enhances neuronal glucose metabolism levels by modulating Pgk1 activity<\/li>\n\n\n\n<li><strong>Preclinical Evidence:<\/strong> Shows potential to improve neuronal energy metabolism disorders and treat neurodegenerative conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-status-amp-next-steps\">Development Status &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Stage:<\/strong> Completed preliminary druggability evaluations<\/li>\n\n\n\n<li><strong>Key Milestones Achieved:<\/strong> Blood-brain barrier penetration confirmed, target engagement demonstrated, initial safety profile established<\/li>\n\n\n\n<li><strong>Next Phase:<\/strong> IND-enabling studies including GLP toxicology, pharmacokinetic optimization, and formulation development<\/li>\n\n\n\n<li><strong>Timeline Projection:<\/strong> Potential IND submission within 18\u201324 months pending successful preclinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands Harbin Gloria&#8217;s CNS portfolio into neurodegenerative diseases, complementing existing therapeutic areas<\/li>\n\n\n\n<li><strong>Academic Partnership Model:<\/strong> Demonstrates effective university-to-industry technology transfer in China&#8217;s pharmaceutical innovation ecosystem<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses significant unmet need in neurodegenerative disorders affecting over 50 million patients globally, with limited disease-modifying therapies available<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Novel Pgk1 targeting mechanism differentiates from amyloid and tau-focused approaches dominating current Alzheimer&#8217;s pipeline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p>The RMB 14.15 million acquisition represents a strategic investment with potential high-value returns if clinical development proves successful. Given the compound&#8217;s early stage, Harbin Gloria maintains flexibility in development pace while securing exclusive global rights to the intellectual property.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines, clinical potential, and commercial expectations for the acquired compound. Actual results may differ due to risks inherent in pharmaceutical development, including preclinical and clinical trial outcomes, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8a89\u8861\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u9996\u90fd\u533b\u79d1\u5927\u5b66\u7b7e\u7f72\u300a\u6280\u672f\u8f6c\u8ba9\uff08\u4e13\u5229\u6743\uff09\u5408\u540c\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8a89\u8861\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u9996\u90fd\u533b\u79d1\u5927\u5b66\u7b7e\u7f72\u300a\u6280\u672f\u8f6c\u8ba9\uff08\u4e13\u5229\u6743\uff09\u5408\u540c\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-780df1e9-d0a4-4727-a4cc-a0cf30e51726\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8a89\u8861\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u9996\u90fd\u533b\u79d1\u5927\u5b66\u7b7e\u7f72\u300a\u6280\u672f\u8f6c\u8ba9\uff08\u4e13\u5229\u6743\uff09\u5408\u540c\u300b\u7684\u516c\u544a.pdf\">\u8a89\u8861\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u9996\u90fd\u533b\u79d1\u5927\u5b66\u7b7e\u7f72\u300a\u6280\u672f\u8f6c\u8ba9\uff08\u4e13\u5229\u6743\uff09\u5408\u540c\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8a89\u8861\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u9996\u90fd\u533b\u79d1\u5927\u5b66\u7b7e\u7f72\u300a\u6280\u672f\u8f6c\u8ba9\uff08\u4e13\u5229\u6743\uff09\u5408\u540c\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-780df1e9-d0a4-4727-a4cc-a0cf30e51726\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1787,1788],"class_list":["post-63083","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gloria-pharmaceuticals","tag-she-002437"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for &quot;An isoquinoline derivative and its synthesis method and application&quot; at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63083\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M\" \/>\n<meta property=\"og:description\" content=\"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for &quot;An isoquinoline derivative and its synthesis method and application&quot; at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63083\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T06:30:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T06:30:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M\",\"datePublished\":\"2026-04-14T06:30:40+00:00\",\"dateModified\":\"2026-04-14T06:30:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gloria Pharmaceuticals\",\"SHE: 002437\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63083#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63083\",\"name\":\"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T06:30:40+00:00\",\"dateModified\":\"2026-04-14T06:30:41+00:00\",\"description\":\"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for \\\"An isoquinoline derivative and its synthesis method and application\\\" at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63083\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63083#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M - Insight, China&#039;s Pharmaceutical Industry","description":"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for \"An isoquinoline derivative and its synthesis method and application\" at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63083","og_locale":"en_US","og_type":"article","og_title":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M","og_description":"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for \"An isoquinoline derivative and its synthesis method and application\" at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.","og_url":"https:\/\/flcube.com\/?p=63083","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T06:30:40+00:00","article_modified_time":"2026-04-14T06:30:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63083#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63083"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M","datePublished":"2026-04-14T06:30:40+00:00","dateModified":"2026-04-14T06:30:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63083"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gloria Pharmaceuticals","SHE: 002437"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63083#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63083","url":"https:\/\/flcube.com\/?p=63083","name":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T06:30:40+00:00","dateModified":"2026-04-14T06:30:41+00:00","description":"Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement with Capital Medical University (CMU), acquiring patent rights for \"An isoquinoline derivative and its synthesis method and application\" at a transaction price of RMB 14.15 million (approximately USD 2 million). The compound represents a preclinical candidate targeting neurodegenerative diseases associated with glucose metabolism disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63083#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63083"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63083#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63083"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63083\/revisions"}],"predecessor-version":[{"id":63085,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63083\/revisions\/63085"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}